
Anne Wojcicki
The David Rubenstein Show
23andMe Therapeutics
23andMe is largely seen as a consumer company. Can you transform your company into being a tech or biotech company by working on disease solutions? That's actually one of the beauties. We have over 50 programs that are in development. And we have two actually in clinical trials. So we're 100 like absolutely thinking about how people will benefit from the human genome.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.